[º¸°ÇŸÀÓÁî] °¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø Ç÷¾×º´¿ø ¹Î±âÁØ(»çÁø ÁÂ), °û´ëÈÆ ±³¼ö(Áß), ±è°¡¿µ ÀÓ»ó°»ç(Ç÷¾×³»°ú) µî ±³¼öÁøÀÌ ÃÖ±Ù ºÎ»ê º¤½ºÄÚ¿¡¼ ¿¸° '2023 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(ICBMT 2023)'¿¡¼ ¿ì¼ö ±¸¿¬ ¹ßÇ¥»ó°ú ¿ì¼ö Æ÷½ºÅÍ ¹ßÇ¥»ó µî °¢Á¾ »óÀ» ¼ö»óÇÔÀ¸·Î½á ÇмúÀû À§»óÀ» ³ô¿´´Ù.
¹Î ±³¼ö´Â 'Autologous stem cell mobilization using high-dose methotrexate and cytarabine combined chemotherapy plus granulocyte colony-stimulating factor for patients with high-risk or relapsed lymphomas (°íÀ§Ç豺 ¶Ç´Â Àç¹ßÇÑ ¸²ÇÁÁ¾ ȯÀÚ¿¡¼ °í¿ë·® ¸ÞÅäÆ®·º¼¼ÀÌÆ®¿Í ½ÃŸ¶óºó º´¿ë ÈÇпä¹ý°ú °ú¸³±¸ Áý¶ô ÀÚ±Ø ÀÎÀÚ¸¦ »ç¿ëÇÑ ÀÚ°¡Á¶Ç÷¸ð¼¼Æ÷ äÁý)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, ¿¬±¸¼º°ú¸¦ ÀÎÁ¤¹Þ¾Ò´Ù.
°û ±³¼ö´Â 'Comparative Analysis Of Graft Sources In Young AML Patients Receiving Matched Sibling Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Is Peripheral Blood Graft Really A Superior Choice Than Bone Marrow Graft?(°í°µµ Àüóġ¸¦ ¹Þ´Â ÀþÀº ÇüÁ¦°£ ÀÌ½Ä ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´ ȯÀÚ¿¡¼ °ñ¼ö Á¶Ç÷¸ð¼¼Æ÷¿Í ¸»ÃÊ Á¶Ç÷¸ð¼¼Æ÷ °£ÀÇ ºñ±³)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, Àç¹ß·üÀÇ Â÷ÀÌ´Â ¾øÀ¸¸é¼ ³·Àº À̽ÄÆí´ë ¼÷ÁÖº´ ¹ß»ý·ü·Î ¿øÀÎÀÓÀ» È®ÀνÃÄ×´Ù.
±è°¡¿µ ÀÓ»ó°»ç´Â 'Correlation between clinical diagnosis and histopathological findings of liver dysfunction after allogeneic-HSCT(Á¶Ç÷¸ð¼¼Æ÷ ÀÌ½Ä ÈÄ °£¼öÄ¡ ÀÌ»óÀ¸·Î °£Á¶Á÷°Ë»ç ½ÃÇàÇÑ È¯ÀÚÀÇ ÀÓ»óÁø´Ü°ú º´¸® ¼Ò°ß ´ëÁ¶)'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥, ¿øÀÎÀÌ ºÒ¸íÈ®ÇÑ È²´Þ ¼öÄ¡°¡ ´Üµ¶ »ó½ÂÇÑ »ç·ÊµéÀÇ Á¶Á÷¼Ò°ßÀÌ ´Ù¾çÇÏ°Ô È®ÀεƴÙ.
Ç÷¾×º´¿ø ÀÌÀç¿í ±³¼ö(»çÁø ¿ì, ¼Ò¾Æû¼Ò³â°ú), ³²È£Çü ÀÓ»ó°»ç(Ç÷¾×³»°ú)´Â ¿ì¼ö Æ÷½ºÅÍ ¹ßÇ¥»óÀ» ¼ö»óÇß´Ù.
ÀÌ ±³¼ö´Â 'Sequential chemotherapy and myeloablative conditioning-based HSCT for pediatric patients with relapsed/refractory acute leukemia'¶ó´Â ÁÖÁ¦·Î, Àç¹ß ¶Ç´Â ºÒÀÀ¼º ¼Ò¾Æ ±Þ¼º¹éÇ÷º´ ȯÀÚ¿¡¼ Ç×¾ÏÄ¡·á Á÷ÈÄ ¿¬¼ÓÀûÀ¸·Î °·ÂÇÑ Àüóġ¸¦ Æ÷ÇÔÇÑ µ¿Á¾Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀ» ½ÃÇàÇÏ´Â °ÍÀÇ Ä¡·á ¼ºÀû ¿¬±¸¸¦ ¹ßÇ¥, ¿¹ÈÄ°¡ ÁÁÁö ¾ÊÀº Àç¹ß ¶Ç´Â ºÒÀÀ¼º ¼Ò¾Æ ±Þ¼º¹éÇ÷º´ ȯÀÚÀÇ ÀÌ½Ä ¼ºÀûÀ» Çâ»ó½Ãų ¼ö ÀÖ´ÂÁö È®ÀÎÇÏ·Á´Â ÁÖ¿ä ¿¬±¸ ¸ñÀûÀ» ´Þ¼ºÇß´Ù.
³²È£Çü ÀÓ»ó°»ç´Â 'Early clinical outcomes of phase 2 trial: dose-reduced ATG and PTCY combination for GVHD prophylaxis in adult patients with acute lymphoblastic leukemia treated with unrelated or haploidentical donor hematopoietic stem cell transplantation'¶ó´Â ÁÖÁ¦¸¦ ¹ßÇ¥Çß´Ù.